TNFSF18 and neoplasm: Experiments performed in vivo with various GITRL recombinant proteins and anti-GITR antibodies prove that the presence of the ligand, either inside the tumor or as a soluble molecule, or treatment with anti-GITR antibody augments CD8+ expansion and activity.